IDEAYA Biosciences Secures FDA Type C Alignment on Dual-Track IDE849 Registrational Strategy in Neuroendocrine Carcinomas
IDEAYA Biosciences aligns with FDA on a dual-track IDE849 strategy: single-arm accelerated approval cohort plus concurrent Phase 3 in neuroendocrine carcinomas.


A dual-track registrational design for IDE849, pairing a single-arm accelerated approval cohort with a concurrent randomized Phase 3, signals how IDEAYA Biosciences is positioning its DLL3-targeting ADC within FDA's post-FDORA accelerated approval framework, a structural model regulatory affairs teams are watching closely across oncology programs.
Following a successful Type C meeting with FDA, IDEAYA plans to initiate a single-arm extension cohort within its ongoing Phase 1/2 trial, enrolling approximately 90 previously treated gastroenteropancreatic NEC (GEP-NEC) patients. Confirmed overall response rate (ORR) assessed by blinded independent central review (BICR), supported by duration of response, will serve as the primary endpoint for a potential accelerated approval application. The company intends to evaluate IDE849 at 2.4 mg/kg and 3.5 mg/kg IV Q3W, doses drawn from its ongoing global Phase 1/2 escalation and expansion trial.
Phase 1/2 data presented at ESMO underpins the accelerated approval rationale: IDE849 demonstrated a 52.6% ORR (10/19) in 2L+ NEC, a median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4%. Grade ≥3 treatment-related adverse event (TRAE) rates were 5% (1/20) at 2.4 mg/kg and 22.2% (4/18) at 3.5 mg/kg, a safety differential that dose-selection committees will weigh carefully as the expansion cohort scales to 90 patients.
The confirmatory Phase 3 is designed to run concurrently, enrolling across multiple NEC subtypes including GEP-NEC and large cell NEC (LC-NEC). Primary endpoints are PFS for accelerated approval conversion and OS for full approval, the latter extending the label to LC-NEC. IDEAYA expects the Phase 3 to be well underway toward full enrollment at the time topline results from the single-arm cohort are available, a sequencing that reflects FDA's current expectation under FDORA that confirmatory trials be initiated, not merely planned, at the time of accelerated approval.
For regulatory affairs leads, the design illustrates a calibrated response to heightened agency scrutiny on post-approval confirmatory commitments: the randomized trial is not contingent on accelerated approval but is structured to run in parallel, reducing the gap between surrogate-endpoint approval and verified clinical benefit. Both registrational trials, along with a separate Phase 3 in post-Imdelltra extensive-stage small cell lung cancer (ES-SCLC), are targeted for initiation by end of 2026.
The pace at which IDEAYA completes enrollment in the 90-patient GEP-NEC cohort and submits its Phase 3 protocol will determine whether the dual-track timeline holds against a competitive DLL3-targeting landscape.
Source: IDEAYA Biosciences newsroom via PR Newswire, 16 November 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
Genentech Gains FDA Approval for Giredestrant Plus Everolimus in Breast Cancer
Cue Biopharma Reports Phase 2 CSU Durability Data and CUE-401 First-in-Human Dosing

Discussion